Chinese Japanese Germany Korea


Indications and Uses Clinical trials Drug interactions Adverse effects Warnings and precautions
Capecitabine structure
Chemical Name:
XELODA;Captabin;RO-9-1978;Chi Pei he;Ro 09-1978;Cpecitabine;Capcitabine;CAPECITABINE;Capecitibine;Capecytabine
Molecular Formula:
Formula Weight:
MOL File:

Capecitabine Properties

Melting point:
Flash point:
storage temp. 
-20°C Freezer
H2O: soluble10mg/mL, clear (warmed)
white to beige
CAS DataBase Reference
154361-50-9(CAS DataBase Reference)
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  T
Risk Statements  45-60-61-68
Safety Statements  53-22-36/37-45
WGK Germany  3
RTECS  HA3852500
HS Code  29349990
Hazardous Substances Data 154361-50-9(Hazardous Substances Data)
Signal word: Danger
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H341 Suspected of causing genetic defects Germ cell mutagenicity Category 2 Warning P201,P202, P281, P308+P313, P405,P501
H350 May cause cancer Carcinogenicity Category 1A, 1B Danger
Precautionary statements:
P201 Obtain special instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection.
P281 Use personal protective equipment as required.
P308+P313 IF exposed or concerned: Get medical advice/attention.

Capecitabine price More Price(12)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 00921 Capecitabine analytical standard 154361-50-9 25mg $58.7 2018-11-13 Buy
Sigma-Aldrich 1090706 Capecitabine United States Pharmacopeia (USP) Reference Standard 154361-50-9 200mg $352.8 2018-11-13 Buy
TCI Chemical C2878 Capecitabine >98.0%(HPLC)(T) 154361-50-9 1g $110 2018-11-22 Buy
TCI Chemical C2878 Capecitabine >98.0%(HPLC)(T) 154361-50-9 5g $377 2018-11-22 Buy
Cayman Chemical 10487 Capecitabine ≥98% 154361-50-9 5g $304 2018-11-13 Buy

Capecitabine Chemical Properties,Uses,Production

Indications and Uses

Capecitabine is a new form of oral fluorinated pyrimidine drug. Capecitabine was developed by Roche Pharmaceuticals, and its commercial name is Xeloda. Capecitabine can change in vivo into 5- FU, an anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate drug that targets cancer cells to inhibit cell division and disrupt RNA and protein synthesis. Its effects are significantly tied to the level of TP enzyme expression in neoplastic tissue and to DPD enzyme in vivo expression. It is suitable as further treatment for advanced primary or metastatic breast cancer patients who have not responded to paclitaxel or anthracycline antibiotics. As an anticancer drug, it is mostly used to treat advanced primary or metastatic breast cancer, as well as in treatment for non-small cell lung cancer, pancreatic cancer, bladder cancer, rectal cancer, colon cancer, gastric cancer, and other solid tumors. Many drugs such as taxanes (paclitaxel, docetaxel, mitomycin, cisplatin, etc.) can increase TP enzyme expression in neoplastic tissues and also have curative effects on gastric cancer. When used in combination with Capecitabine, these drugs can also improve Capecitabine’s anticancer abilities and produce synergistic effects.

Clinical trials

Analyses of nearly 400 randomized comparisons of clinical outcomes show that a combination of adriamycin, cisplatin or oxaliplatin with 5-FU, compared to a combination of these drugs with Capecitabine, has a two-fold difference in curative efficacy and lowers toxicty. A large-scale Chinese clinical trial of Capecitabine in combination with DDP in the treatment of stage II gastric cancer also proves its advantages of high efficacy, low toxicity, and affordability.

Drug interactions

Currently, there are no side effects of clinical significance when used in combination with antihistamines, NSAIDs, morphine, paracetamol, aspirin, antiemetic drugs, and H2 receptor antagonist drugs.
Capecitabine’s binding rate with serum protein is relatively low (64%), and its possibility of interacting through substitution with drugs that bind closely with proteins is currently unknown. In external experiments, Capecitabine has not shown any influence on human liver microsomal P450 enzyme.
If any phenytoin and coumarin derivatives anticoagulants are used in combination with Capecitabine, dosages should be lowered.

Adverse effects

Common adverse reactions include nausea, vomiting, oral ulcers, abdominal pain, diarrhea, loss of appetite, and skin changes. There have also been reports of some patients experiencing transient myelosuppression, hair loss, tears, headache, and dizziness.

Warnings and precautions

Capecitabine is a bone marrow inhibitor; a blood exam must be administered before every usage to monitor blood cell and platelet count.
This product poses toxic side effects to the liver, so liver functions must be routinely examined. Additionally, heart functions should also be monitored to prevent irreversible toxic reactions. If venous transfusion of the drug is required, the aforementioned organ functions should be tested for suitability before administration. Capecitabine may cause damage to embryos, thus making it unsuitable for pregnant women. Women using this drug are also not suitable for pregnancy. Even after treatment is ended, this drug may have some impact on fertility.


Capecitabine is a new oral fluoropyrimidine carbamate for patients with advanced neoplastic disease, approved as Xeloda for the treatment of refractory metastatic breast cancer after failure on Paclitaxel and an anthracycline-based chemotherapy regimen ; it is a prodrug of doxifluridine (5-fluorouracil ; 5-FU) activated by a cascade of 3 enzymes concentrated in human liver and cancer tissue, resulting in the selective release of 5-FU at the tumor site and offering a prolonged tumour exposure to 5-FU. Oral Capecitabine passes intact through the intestinal mucosa, is converted first by carboxylesterase to 5'-deoxy-5- fluorocytidine in the liver, then by cytidine deaminase to 5'-deoxy-5-fluorouridine in the liver and tumour tissues and finally by thymidine phosphorylase to 5-FU in tumors. Therefore, Xeloda is much safer and more effective than 5-FU (for example, in the HCT116 human colon cancer and the MX-1 breast cancer xenograft .models).

Chemical Properties

Colourless solid


Roche (Switzerland)


An antineoplastic agent. A prodrug of doxifluridine.


Capecitabine is an antineoplastic agent. Capecitabine is a prodrug of Doxifluridine (D556750).


An antiproliferative 5-fluorouracil releasing compound


ChEBI: A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted to its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agen used in the treatment of cancers.

brand name

Xeloda (Roche).

General Description

The drug is available in a 150- and 500-mg tablets for oraluse. This drug is a fluoropyrimidine carbamate prodrugform of 5-fluorouracil (5-FU). It is used to treat breast cancerand colorectal cancer. The drug is converted to 5-FU bythe enzyme thymidine phosphorylase following esterase activity to hydrolyze the carbamate moiety and deamination.Capecitabine is readily absorbed by the GI tract, and peakplasma levels of 5-FU occur about 2 hours after oral administration.Indications, drug interactions, and toxicities areequivalent to those of 5-FU.

Capecitabine Preparation Products And Raw materials

Raw materials

Preparation Products

Capecitabine Suppliers

Global( 444)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Jinan Jianfeng Chemical Co., Ltd
15562555968 CHINA 617 58
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19954 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22043 58
Chengdu Henghui Pharm Tec Co. Ltd.
13540674322 15828370308,QQ:2879822141
028-89481236 CHINA 121 55
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Hebei Jiangkai Trading Co., Ltd
0086-17197824289/17197824028 CHINA 277 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555 CHINA 1374 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32651 55

View Lastest Price from Capecitabine manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-04-11 Capecitabine
US $1.00 / kg 1kg 99% 500KG Hebei Jimi Trading Co., Ltd.
2018-07-26 Capecitabine
US $100.00 / KG 1KG 99% Customized career henan chemical co
2018-07-25 Capecitabine
US $100.00 / KG 1KG 98% 100KG career henan chemical co

154361-50-9(Capecitabine)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved